| Vol. 9.15 – 21 April, 2021 |
| |
|
|
| Scientists demonstrated the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike receptor binding domain displayed on a protein nanoparticle, to stimulate robust and durable neutralizing antibody responses and protection against SARS-CoV-2 in non-human primates. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators identified an emerging SARS-CoV-2 variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California. [Cell] |
|
|
|
| Scientists highlight the coordinated immune response that contributed to COVID-19 pathogenesis and revealed discrete cellular components that could be targeted for therapy. [Nature Medicine] |
|
|
|
| Researchers report that another emergent variant from Brazil, P.1, was not only refractory to multiple neutralizing monoclonal antibodies, but also more resistant to neutralization by convalescent plasma and vaccinee sera. [Cell Host & Microbe] |
|
|
|
| The authors compared SARS-CoV-2 sequences from natural and experimental mustelid infections and identified two surface glycoprotein spike mutations associated with mustelids. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators showed that classically activated M1 alveolar macrophages (AMs) facilitated viral spread; however, alternatively activated M2 AMs limited the spread. [Cell Discovery] |
|
|
|
| Researchers identified distinct signatures of microbial dysbiosis among severely ill COVID-19 patients on broad spectrum antimicrobial therapy. [Cell Discovery] |
|
|
|
| The authors describe the efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on the spike glycoprotein of SARS-CoV-2. [npj Vaccines] |
|
|
|
| Investigators showed preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that encoded full-length, pre-fusion stabilized SARS-CoV-2 spike protein. [npj Vaccines] |
|
|
|
| Scientists found that human iPS cells expressing the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) could be infected with SARS-CoV-2. In infected ACE2-iPS cells, the expression of SARS-CoV-2 nucleocapsid protein, budding of viral particles, production of progeny virus, double membrane spherules, and double-membrane vesicles were confirmed. [iScience] |
|
|
|
MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
| | The authors showed that pediatric Pandemrix-associated NT1 patients had enhanced T-cell immunity against the viral epitopes, neuraminidase 175–189 and nucleoprotein 214–228. [Nature Communications] |
|
|
|
| Researchers showed that suitable nucleic acid was sufficient to trigger a dynamic transformation of VP40 dimer into the octameric ring. [Cell Reports] |
|
|
|
| Scientists examined the role of Mint3 in macrophages, which promoted glycolysis via hypoxia-inducible factor-1 activation, during the initiation of pyroptosis following Listeria monocytogenes infection. [Cell Death & Disease] |
|
|
|
|
| The authors review the precedent for passive immunization and lessons learned from using antibody therapies for viral infections such as respiratory syncytial virus, Ebola virus and SARS-CoV infections. [Nature Reviews Immunology] |
|
|
|
|
| Trevena, Inc. announced that TRV027, the company’s novel AT1 receptor selective agonist, has been selected for inclusion in an international, multi-site, adaptive, Phase II-Phase III trial in COVID-19 patients. [Trevena, Inc. (Globe Newswire, Inc.)] |
|
|
|
|
| May 10 – 15, 2021 Virtual |
|
|
|
|
|
| Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| The University of Warwick – Coventry, England, United Kingdom |
|
|
|
| IPBS-Toulouse – Toulouse, France |
|
|
|
|